Genprex, Inc.
GNPXCIK 0001595248 · Pharmaceutical Preparations · Nasdaq
Revenue (TTM)
$0
Q1 May 2026
Net Income (TTM)
−$16.9M
+23.1% YoY
Q1 May 2026
EPS Diluted (TTM)
—
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
−$19.64M
Q1 May 2026
Cash
$18.05M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
10.59M sh
Q1 May 2026
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.
Balance Sheet
Cash vs Debt
Latest news
All news →-
Routine Neutral
Genprex Restates 2018 Equity Incentive Plan, Effective April 15
The biotech company amended and restated its stock-award plan to reflect regulatory changes and prior reverse stock splits.